◈ Nootpedia
Compact view
Research pass: thorough Pharmaceutical · Oral WATCH-LIST LOW

9-Methyl-β-carboline

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict WATCH-LIST LOW

Polanski lab body of work (2007-2020, multiple replicated rat + cell-culture papers) is genuinely substantial preclinical evidence for a multimodal dopaminergic neurorestorative profile rare in the nootropic literature — TH upregulation, hippocampal dopamine elevation, dendritic outgrowth, BDNF/artemin induction, anti-inflammatory microglial effects, MPP+ neuron rescue. BUT: zero human trials of any kind, dual MAO-A/B inhibition (not the "selective MAO-B" some sources claim — IC50 favors MAO-A 15.5×) raises tyramine + serotonin-syndrome theoretical concerns at chronic dosing, documented UVA-photosensitization with DNA damage in cell models is a real and largely unquantified human risk, vendor identity verification is non-trivial for a research-chem with limited Trustpilot history, and the V5 stack already covers neurogenic + dopaminergic axes (cerebrolysin, bromantane, semax/adamax, low-dose selegiline) with vastly better human safety data. WATCH-LIST not SKIP because the mechanism profile is genuinely interesting and biohacker reports skew positive at 5-15 mg, but the risk/benefit at age 20 with strong V5 alternatives makes "wait for human safety data or independent replication" the correct call. Would upgrade to OPTIONAL-ADD only if (a) a human Phase 1 / observational safety study lands, (b) photosensitivity is quantified at biohacker doses (not just UVA cell-culture), or (c) Dylan develops a specific dopaminergic-deficit indication (post-modafinil tolerance, post-stim tolerance reset).

Research pass: thorough
▸ Decision matrix by user profile Per-archetype
  • Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype)
    WATCH-LIST

    Mechanism is interesting and overlaps Dylan's brain-preservation thesis (multimodal dopaminergic + neurogenic + anti-inflammatory). But: zero human data, photosensitization concern at outdoor MMA training, V5 stack already covers the same axes (cerebrolysin + bromantane + selegiline + Adamax/Semax) with vastly better human evidence. Hold for human safety data or Dylan-specific dopaminergic-deficit indication. If trialed eventually: post-V5-stable, single-variable 5→15 mg titration with photosensitivity check.

  • 30-50, executive maintenance
    WATCH-LIST

    If user has stimulant-tolerance issue or specific anhedonia signal, low-dose 9-Me-BC (5-10 mg) is one of the more mechanistically rational research-chem options. Selegiline (Rx, low-dose) is the better default if sourceable. Photosensitivity caution applies.

  • 50+, mild cognitive decline
    WATCH-LIST

    Multimodal mechanism (anti-inflammatory + dopaminergic + neurotrophic + α-synuclein-reducing) is exactly right for the indication, and the Polanski papers explicitly position this as a candidate Parkinson's drug. But: no human data, no human safety profile, and selegiline + rasagiline have the actual evidence base for PD-relevant DA preservation in this demographic. Watch for human studies; in the meantime, conventional DA-preservation tools (selegiline + standard PD prevention) win.

  • Anxiety-prone
    SKIP

    ~10-20% of biohacker users report anxiety/aggression at higher doses. Mechanism (MAO-A inhibition + dopaminergic enhancement) can worsen anxiety in vulnerable users. Better picks: bromantane (anxiolytic arm), selegiline (cleaner DA preservation), or non-DA compounds.

  • High athletic load, tested status
    SKIP

    if WADA-tested. β-carbolines are not formally WADA-banned as of 2026, but the broader MAO-inhibition + dopaminergic-enhancement profile has historically attracted scrutiny. For untested status (Dylan): the photosensitization concern is the bigger issue with outdoor MMA / cardio training.

  • Sleep-disordered
    CAUTIOUS

    AM dosing typically preserves sleep; some users report increased dream vividness (MAO-A → REM-relevant monoamine signaling). Avoid PM dosing. If insomnia worsens, discontinue.

  • Recovery-focused (post-injury, post-illness)
    WATCH-LIST

    Anti-inflammatory + neurotrophic profile is mechanistically appropriate for recovery contexts. Photosensitization concern applies. Cerebrolysin, BPC-157, semax/adamax all have better evidence bases for the recovery indication.

  • Strength/anabolic-focused
    OPTIONAL-WITH-CAVEATS

    Bodybuilding community uses 9-Me-BC for stimulant-tolerance reset during deload weeks; mechanism plausibility is real but the use case is supported by anecdote. If trialed: standard 10-15 mg / 2-week cycle during stimulant off-week.

▸ Subjective experience (deep)

Synthesized from biohacker reports (Longecity, Reddit r/Nootropics, blog reviews, Hydrapharm-product user reviews):

Onset: No first-dose acute effect for most users — this is not a felt-immediately compound. Effects emerge over days 2-7, consistent with the gene-expression mechanism (TH upregulation, neurotrophic factor induction, MAO inhibition reaching steady state). Some users report mild AM stim-like alertness within hours of dosing, but the headline cognitive/mood effects build over 1-2 weeks.

Peak phenomenology (week 2-4 of consistent dosing):

  • Mild dopaminergic lift — motivation, drive, "wanting to do things"
  • Mood-bright — not euphoric, not stim-rushed; more "background floor raised"
  • Decreased anhedonia — subset reports more reliably than other dopaminergic compounds
  • Focus / cognitive lift — moderate, less than modafinil, comparable to mid-range bromantane
  • Libido enhancement — common (consistent with dopaminergic mechanism)
  • Sleep usually preserved if dosed AM
  • Some users report increased dream vividness (consistent with MAO-A inhibition extending REM-relevant monoamine signaling)

Failure modes (~30-40% of users):

  • "Felt nothing" after 2-4 weeks at 10-15 mg
  • Subset reports anxiety/edge at >20 mg
  • Sublingual users report persistent taste loss / sweetness numbing for 1-2 weeks after stopping (this is the most common complaint in the SL-route discussion threads — appears to be local nerve effect, recovers but unpleasant)
  • Headache, GI upset (early dosing)

Compared to:

  • Selegiline (low-dose oral 1-2.5 mg): Selegiline is cleaner, has 40+ years of human data, and at low dose is MAO-B-selective without MAO-A risk. Subjective effect is similar genre (mild dopaminergic lift) but selegiline has the human-evidence base 9-Me-BC entirely lacks.
  • Bromantane: Bromantane is the closer comparator subjectively — both are slow-onset (5-7 day buildup), both work via TH upregulation (different upstream mechanism but same pharmacological endpoint), both are calm-stimulant rather than wired. Bromantane has the 728-pt Russian asthenia trial (open-label but human); 9-Me-BC has zero human data.
  • NSI-189: Both target hippocampal neurogenesis-related endpoints. NSI-189 has 3 human Phase 2 trials (all failed primary endpoint); 9-Me-BC has zero. NSI-189 is depression-focused; 9-Me-BC is dopamine + cognition-focused.
  • Modafinil: Different category — modafinil is wakefulness-promoter with much larger acute effect; 9-Me-BC is slow-onset neurorestorative. Not direct competitors.
▸ Tolerance + cycling deep dive
  • Tolerance buildup: Unknown / unclear. Some users report sustained effect across 4 weeks; others report fade after 2-3 weeks. Mechanism (gene expression) would predict slow tolerance development (similar to bromantane), but no controlled tolerance studies exist.
  • Recommended cycle: 2 weeks on / 2 weeks off (community consensus). Maximum 4 weeks continuous before mandatory break. Long-term continuous use is uncharacterized in any species — animal studies are typically 2-4 week dosing windows.
  • Reset protocol: 2-4 weeks complete off-cycle. No formal reset protocol documented.
▸ Stacking deep dive

Synergistic with

  • Bromantane: Mechanistically complementary — bromantane upregulates TH via cAMP/PKC + CpG demethylation; 9-Me-BC upregulates TH via PI3K/Akt + transcription-factor (Gata2/3, Creb) induction. Different upstream paths to the same dopamine-synthesis endpoint. Theoretical synergy. No empirical data, no biohacker reports of the specific combination. If trialed: not simultaneously initiated — wait until bromantane is at steady state (week 4-6) before adding 9-Me-BC as a single-variable test.
  • NSI-189: Both hippocampal neurogenesis-tropic, different molecular routes (NSI-189: BDNF + GDNF + VEGF + SCF; 9-Me-BC: BDNF + artemin + NT-3 via astrocyte recruitment). Stacking is biologically rational; both are research-chems with thin human evidence so layering two unknowns multiplies uncertainty.
  • Cerebrolysin: Could plausibly combine — cerebrolysin delivers neurotrophic peptide fragments parenterally; 9-Me-BC induces endogenous neurotrophic factor expression. Different mechanisms, similar endpoint. No data.
  • Apigenin: Apigenin is a MAO-A/B inhibitor in vitro at high doses; combination would likely be additive rather than synergistic. Avoid stacking at high doses of either.

Avoid stacking with

  • Selegiline: MAO-overlap concern. Selegiline at 1-2.5 mg oral is MAO-B-selective (~90% selectivity); 9-Me-BC inhibits both MAO-A (preferentially) and MAO-B. Stacking adds MAO-A inhibition on top of selegiline's MAO-B inhibition — effectively converting the combination into a non-selective MAOI regimen, with full tyramine restriction and serotonergic-drug interaction profile. Do not stack. If choosing between them, selegiline has 40+ years of human data; 9-Me-BC has zero. Selegiline wins by default.
  • Other MAOIs (rasagiline, moclobemide, tranylcypromine, phenelzine, isocarboxazid): Same logic — additive MAO inhibition. Avoid.
  • SSRIs / SNRIs / TCAs / tramadol / MDMA / high-dose DXM / St. John's Wort: Theoretical serotonin-syndrome risk via MAO-A inhibition arm. Avoid.
  • Other β-carbolines (harmine, harmaline, ayahuasca, Syrian rue extract): Additive MAO inhibition + DNA-photosensitization risk. Avoid.
  • Stimulants at high dose (amphetamine-class): MAO-A inhibition will potentiate amphetamine-induced monoamine release — hypertensive risk. Modafinil is theoretically lower-risk (no monoamine-release mechanism) but caution with combined cardiovascular load.
  • Levodopa: Theoretical risk of excessive peripheral catecholamine accumulation. Avoid.

Neutral / safe co-administration (mechanistically reasonable, low interaction risk)

  • V4 stack (DHA, magnesium, citicoline, NAC, phosphatidylserine, curcumin, rhodiola, theanine, glycine→tryptophan, D3+K2, beta-alanine, vitamin C) — no expected interactions
  • Creatine
  • Adamax / Semax / N-acetyl-Semax-Amidate (peptides, different mechanism, no MAO interaction)
  • BPC-157 / TB-500 (peptides, no CNS monoamine interaction)
  • Cerebrolysin (peptide fragments, no MAO/monoamine interaction)
  • L-tyrosine (substrate-side support for the TH that 9-Me-BC upregulates — theoretically additive; no documented hazard)
  • ALCAR (mitochondrial, no MAO interaction)

Bromantane comparison — pick ONE for now

Bromantane is mechanistically similar (TH upregulation, slow onset, calm-stimulant profile) and has substantially more human evidence (Russian 728-pt trial, ~20 years of clinical use, established pharmacokinetics). For Dylan, bromantane is the better pick at the TH-upregulation slot. 9-Me-BC offers (a) BDNF/artemin/NT-3 multi-trophic factor induction (bromantane's BDNF effect is less well-characterized), (b) hippocampal dendritic effects (bromantane's hippocampal effects are thinner), and (c) a different upstream mechanism that could be additive. But until there is human safety data on 9-Me-BC, the right move is bromantane primary; 9-Me-BC remains a watch-list compound that could layer on later if the human evidence base develops.

▸ Drug interactions deep dive
  • CYP enzymes: Not characterized in humans. β-carboline class can inhibit CYP1A2 (relevant for caffeine, theophylline, melatonin metabolism) — extrapolation, not 9-Me-BC-specific data.
  • MAO-A inhibition: Drives the drug-interaction profile (see "Avoid stacking with" above). All serotonergic medications are theoretical concerns.
  • MAO-B inhibition: Compounds the MAO-A profile but additionally implicates dopamine and PEA metabolism.
  • Tyramine (dietary): Theoretical pressor reaction. Aged cheese, fermented soy (miso, tempeh, soy sauce in quantity), tap beer, cured/aged meat, marmite/vegemite, broad beans. Daily caution if dosing chronically.
  • Photosensitizing drugs: Theoretical additive photosensitization (tetracyclines, fluoroquinolones, hydrochlorothiazide, retinoids, St. John's Wort, NSAIDs at high dose). Avoid combination if also dosing 9-Me-BC.
▸ Pharmacogenomics

Minimal data. No 9-Me-BC-specific pharmacogenomic studies exist. Inferred relevance:

  • CYP1A2 polymorphisms (relevant if 9-Me-BC is CYP1A2-metabolized like other β-carbolines — unconfirmed for 9-methyl variant). CYP1A2 ultra-rapid metabolizers might see lower exposure; poor metabolizers higher exposure.
  • MAO-A VNTR (the upstream/promoter VNTR in the MAOA gene): high-activity carriers (3R/4R alleles) might be less affected by 9-Me-BC's MAO-A inhibition; low-activity carriers (2R/3R, "warrior gene" framing) might experience more pronounced MAO-A-related effects.
  • DRD2 Taq1A: A1 allele carriers (lower D2 receptor density) might benefit more from dopaminergic lift; A2/A2 might experience less marginal benefit.
  • For Dylan post-23andMe (June 2026): review MAOA VNTR + DRD2 Taq1A alongside selegiline analysis. If genotype suggests low-DA-tone, the case for any of the dopaminergic compounds (selegiline > bromantane > 9-Me-BC) strengthens.
▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
Research-chem Kimera Chems ~$62-67 / 1 g powder or 60×20 mg caps Medium (mixed Trustpilot 3.8★, Knoji 2.3★ — last resort vendor for research-chem-only compounds) US-based; CoA verification recommended; Dylan's existing relationship for TAK-653 / Dihexa / ACD-856
Research-chem PureRawz varies — typical $40-80 / unit Medium (3rd-party testing claimed; established in research-chem space) Lab reports available
Research-chem Modern Aminos ~$50-70 / 60×15 mg caps Medium (newer vendor, US-made claim) 3rd-party testing claimed
Research-chem RCD.bio varies Medium Liquid form available
Branded supplement Hydrapharm 9-MBC ~$60-80 / 60×15 mg caps when in stock Medium-high (established brand, but inventory unreliable as of 2026) Currently appears discontinued or out-of-stock at major retailers
Branded supplement RCpeptides varies / 25 mg caps Medium Smaller vendor
AVOID Everychem — LOW (basement-lab accusations) Per encyclopedia AVOID list

Sourcing strategy for Dylan if/when trialed:

  • Primary: Kimera Chems (existing vendor relationship, CoA verification)
  • Secondary: PureRawz or Modern Aminos with 3rd-party COA
  • Avoid sublingual liquid formulations (taste-loss issue is universal, not vendor-specific)
  • Identity verification: HPLC/MS ideal, mp / UV-Vis acceptable for research-chem-tier verification
  • Cost estimate: $40-80/month at 10-15 mg/day with 2-on/2-off cycling
▸ Biomarkers to track (deep)

  • Baseline (before starting):

    • Resting BP, orthostatic BP, HR
    • PHQ-9 + SHAPS (anhedonia scale) + motivation self-rating
    • Sleep-onset latency baseline (1 week diary)
    • ALT/AST, CBC
    • Skin photosensitivity baseline (subjective + any actinic-exposure history)
    • If post-23andMe: review MAOA VNTR, DRD2 Taq1A, CYP1A2*1F status

  • During use:

    • Daily: subjective mood/motivation 1-10, sleep quality 1-10, photosensitivity skin reaction y/n
    • Weekly: PHQ-9, SHAPS, BP/HR check
    • Week 2 + week 4: ALT/AST if cycling repeatedly

  • Post-cycle (if cycled):

    • 1-week and 4-week post-discontinuation: same panel as during use
    • Watch for "post-cycle anhedonia" or mood drop (indicating the dopaminergic lift was carrying the user)
    • Photosensitivity check at 1 week post-stop (effect should resolve)
▸ Controversies / open debates Live debate

  1. "MAO-B selective" vs "MAO-A preferential" — biohacker-literature accuracy gap. Many nootropic blogs and even the prior encyclopedia framing characterize 9-Me-BC as "MAO-B inhibitor + dopaminergic" — implying selegiline-like MAO-B selectivity. The actual published IC50 data shows the opposite: MAO-A IC50 1 μM, MAO-B IC50 15.5 μM, ratio 15.5× more potent at MAO-A. The molecule is MAO-A-preferential at the enzyme level. This matters for tyramine + serotonin-syndrome risk framing. This compound file deliberately corrects the prior encyclopedia framing. — Flag for accuracy.

  2. Photosensitivity translation: cell-model UVA → human cancer risk? The DNA-damage data (8-oxo-dG, single-strand breaks, micronuclei) is real and reproducible in cell culture under UVA exposure. Whether chronic biohacker dosing + ambient sun exposure produces measurable mutagenic load in human skin in vivo is unstudied. The biohacker community largely treats this as "stay out of strong sun" advice; a more conservative reading would be "this is a demonstrably DNA-damaging compound under conditions that occur during normal life and the safety data to dismiss this concern doesn't exist."

  3. Anti-Parkinson positioning vs no human translation in 15+ years. The Polanski group has explicitly positioned 9-Me-BC as "a new anti-Parkinson drug" since 2010 (PMID 21651332). 16 years later there is no Phase 1 trial registered, no pharma development program, no IND filing visible in public databases. Why? Possible explanations: (a) IP constraints — 9-Me-BC is not novel chemistry and is unpatentable, removing pharma incentive; (b) the photosensitivity/DNA-damage data is a development-killing liability that the academic group has not formally acknowledged but a pharma development team would not accept; (c) animal-to-human translation has not been demonstrated and the risk of expensive failure deters investment. This is the single most important "absence of evidence" signal in the 9-Me-BC file — substantial preclinical body of work + zero translation in 16 years suggests a hidden barrier.

  4. "Neurogenesis" claim — true neurogenesis vs dendritic remodeling? The Gruss 2012 hippocampal-dendrite paper documents dendritic outgrowth and synaptic proliferation in dentate gyrus, plus elevated hippocampal dopamine. Whether this represents true adult neurogenesis (BrdU-positive new neuron birth from dentate progenitors, à la NSI-189) or dendritic + synaptic remodeling of existing neurons is not fully resolved in the published data. The "neurogenesis" framing in the encyclopedia and biohacker literature may be slightly stronger than the data supports. — Flag for accuracy.

  5. Mitochondrial biogenesis claim — class extrapolation vs direct data. "Mitochondrial biogenesis (AMPK → PGC-1α)" is a plausible mechanism class-level inference but is not directly demonstrated for 9-Me-BC in published assays. The complex-I rescue in MPP+-treated rats is documented; the upstream AMPK/PGC-1α pathway involvement is inferred from class pharmacology. — Flag for accuracy.

  6. "Substantial Polanski body of work" caveat. Polanski/Wagner/Gruss is a single research group across most of the primary literature. Independent replication outside this group is thinner than the bulk paper count suggests. Keller 2020 (PMC8592951) is from the same general research environment. True independent multi-lab replication of the headline endpoints (TH upregulation, BDNF doubling, hippocampal cognition gain) is limited. — This is a softer accuracy flag than a hard one but worth noting.

▸ Verdict change log
  • 2026-05-05 — Initial verdict: WATCH-LIST, confidence LOW. Mechanism is unusually multimodal and the Polanski preclinical body is more substantial than most research-chems, but zero human data + photosensitization concern + V5 stack already covering same axes + 15+ years of stalled pharma translation = wait. Would upgrade to OPTIONAL-ADD on (a) human Phase 1, (b) photosensitivity quantification at biohacker doses, or (c) Dylan-specific dopaminergic-deficit indication.
▸ Open questions / gaps Open
  1. Human pharmacokinetics: completely empty. No published Cmax, Tmax, half-life, bioavailability, or metabolism data in humans for any route. The "15-24 hour half-life" is biohacker-community estimate, not measured.
  2. Human safety: completely empty. No Phase 1 healthy-volunteer study has been published or registered. All safety framing is animal + biohacker-anecdote.
  3. Photosensitivity in vivo human: The cell-model UVA data is robust; whether equivalent damage occurs in human skin at biohacker doses with normal sun exposure is unstudied.
  4. MAO-A inhibition in vivo at human doses: 1 μM IC50 is the in vitro number. What plasma + brain concentration 5-15 mg oral produces in humans, and whether that reaches MAO-A inhibitory levels, is unknown. Clinical relevance of the "theoretical tyramine reaction" depends on this.
  5. Long-term safety beyond 4 weeks: Animal studies are typically 2-4 week dosing windows. Chronic-dose toxicology is uncharacterized in any species.
  6. Dose-response in humans: Whether 5 mg, 15 mg, or 30 mg is the optimal dose, and whether the bell-shape seen in cell culture (33% TH increase peak at 90 μM, declining at 125+ μM) translates to a human dose-response curve, is unknown.
  7. Independent replication outside Polanski group: Most primary literature is from Bremen/Wagner/Polanski/Gruss collaborators. Independent multi-lab replication of headline endpoints is thinner than the citation count suggests.
  8. Why no pharma development in 16 years: The most informative open question. IP barriers? Hidden toxicology? Translation failure? Some combination?
▸ Sources (full, with our context)
Back to compact view